← Leaderboards
Paul D Lampe
Fred Hutchinson Cancer Center
$17,368,376
Attributed
$26,567,407
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,567,407 · 19
By mechanism
U01$11,919,071 · 4
R01$10,182,708 · 3
P50$2,984,766 · 3
T32$461,617 · 1
R21$415,339 · 1
U54$364,262 · 1
Top collaborators
- A. Mcgarry Houghton14 shared
- Charles Drescher7 shared
- Christopher I Li7 shared
- Samir M Hanash5 shared
- Delphine L Chen3 shared
- Brian Matthew Zeglis3 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- A. McGarry Houghton$19,684,845
- Jonathan A. Cooper$21,239,984
- Peter S Nelson$31,175,698
- Stanley R Riddell$31,084,866
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsAntibodiesMalignant NeoplasmsCessation Of LifeSamplingProteomicsValidationPlasmaAutoantibodiesDiagnosisCancer EtiologyComplexMalignant Neoplasm Of LungScreeningGap JunctionsPhosphorylationSiteCellsSurvival RatePlayLungDiagnosticBaseBiological Markers
Grant awards (67)
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer$645,551
R01 · FY2025 · CA · contact PI
Developmental Research Program$308,965
P50 · FY2025 · CA · contact PI
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer$613,760
R01 · FY2024 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$406,116
R01 · FY2024 · CA
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer$582,047
R01 · FY2023 · CA · contact PI
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkers$516,213
P50 · FY2023 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$431,826
R01 · FY2023 · CA
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkers$516,213
P50 · FY2022 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$273,780
R01 · FY2022 · CA
Tumor-specific autoantibodies for SCLC early detection$148,883
R01 · FY2022 · CA
Tumor-specific autoantibodies for SCLC early detection$432,640
R01 · FY2021 · CA
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$418,953
U01 · FY2021 · CA
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkers$395,452
P50 · FY2021 · CA · contact PI
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkers$119,970
P50 · FY2021 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$836,410
U01 · FY2020 · CA
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkers$594,498
P50 · FY2020 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$573,272
R01 · FY2020 · CA
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$166,534
U01 · FY2020 · CA
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$779,890
U01 · FY2019 · CA
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkers$533,455
P50 · FY2019 · CA · contact PI
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$467,030
U01 · FY2019 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$1,085,901
U01 · FY2018 · CA
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$481,475
U01 · FY2018 · CA · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$972,870
U01 · FY2017 · CA
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$516,409
U01 · FY2017 · CA · contact PI
Phosphorylation of Gap Junction Proteins$393,270
R01 · FY2017 · GM · contact PI
Breast, Colorectal, and Ovary Cancer Clinical Validation Center$1,011,430
U01 · FY2016 · CA
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$494,170
U01 · FY2016 · CA · contact PI
Phosphorylation of Gap Junction Proteins$393,270
R01 · FY2016 · GM · contact PI
Proteomic, Glycomic and Autoantibody Lung Cancer Biomarker Validation$372,766
U01 · FY2016 · CA · contact PI
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$513,793
U01 · FY2015 · CA · contact PI
Phosphorylation of Gap Junction Proteins$393,270
R01 · FY2015 · GM · contact PI
Proteomic, Glycomic and Autoantibody Lung Cancer Biomarker Validation$364,038
U01 · FY2015 · CA · contact PI
Affinity Based Strategies to Fast Track Development of Colon Cancer Biomarkers$584,841
U01 · FY2014 · CA · contact PI
Phosphorylation of Gap Junction Proteins$393,270
R01 · FY2014 · GM · contact PI
Proteomic, Glycomic and Autoantibody Lung Cancer Biomarker Validation$349,811
U01 · FY2014 · CA · contact PI
Affinity Based Strategies to Fast Track Development of Colon Cancer Biomarkers$576,207
U01 · FY2013 · CA · contact PI
Phosphorylation of Gap Junction Proteins$359,322
R01 · FY2013 · GM · contact PI
Affinity Based Strategies to Fast Track Development of Colon Cancer Biomarkers$610,846
U01 · FY2012 · CA · contact PI
Phosphorylation of Gap Junction Proteins$372,623
R01 · FY2012 · GM · contact PI
Cx43 phosphorylation modulates Kras mediated pancreas cancer progression$177,961
R21 · FY2012 · CA · contact PI
Affinity Based Strategies to Fast Track Development of Colon Cancer Biomarkers$657,567
U01 · FY2011 · CA · contact PI
Phosphorylation of Gap Junction Proteins$372,884
R01 · FY2011 · GM · contact PI
CX43 IN MITOSIS$24,666
P41 · FY2011 · RR · contact PI
Cx43 phosphorylation modulates Kras mediated pancreas cancer progression$7,698
R21 · FY2011 · CA · contact PI
Affinity Based Strategies to Fast Track Development of Colon Cancer Biomarkers$658,130
U01 · FY2010 · CA · contact PI
Phosphorylation of Gap Junction Proteins$376,907
R01 · FY2010 · GM · contact PI
Cx43 phosphorylation modulates Kras mediated pancreas cancer progression$229,680
R21 · FY2010 · CA · contact PI
CX43 IN MITOSIS$11,941
P41 · FY2010 · RR · contact PI
Interdisciplinary Training in Cancer Research Training Grant$461,617
T32 · FY2009 · CA · contact PI
Phosphorylation of Gap Junction Proteins$329,247
R01 · FY2009 · GM · contact PI
Phosphorylation of Gap Junction Proteins$253,744
R01 · FY2009 · GM · contact PI
Laboratory Assay Performance, Coordination & Oversight Core$241,720
U54 · FY2009 · CA · contact PI
CX43 IN MITOSIS$15,584
P41 · FY2009 · RR · contact PI
Phosphorylation of Gap Junction Proteins$329,247
R01 · FY2008 · GM · contact PI
Laboratory Assay Performance, Coordination & Oversight Core$122,542
U54 · FY2008 · CA · contact PI
CX43 IN MITOSIS$9,756
P41 · FY2008 · RR · contact PI
Phosphorylation of Gap Junction Proteins$329,247
R01 · FY2007 · GM · contact PI
CX43 IN MITOSIS$10,853
P41 · FY2007 · RR · contact PI
Phosphorylation of Gap Junction Proteins$339,080
R01 · FY2006 · GM · contact PI
Phosphorylation of Gap Junction Proteins$278,643
R01 · FY2005 · GM
Proteomic Biomarkers of Health Behaviors$83,376
R03 · FY2005 · CA
Proteomic Biomarkers of Health Behaviors$83,468
R03 · FY2004 · CA
Phosphorylation of Gap Junction Proteins$278,814
R01 · FY2003 · GM
Phosphorylation of Gap Junction Proteins$300,136
R01 · FY2002 · GM
Phosphorylation of Gap Junction Proteins$338,428
R01 · FY2001 · GM
PHOSPHORYLATION OF GAP JUNCTION PROTEINS$243,431
R01 · FY2000 · GM